Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FPPA2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,284
Award facts
- Contract value 100% obligated
- $9,284.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $9,284.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The award, issued on October 17, 2025, with an ultimate completion date of November 7, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will fulfill this delivery order under its single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion Defense Logistics Agency acquisition strategy establishing multiple regional prime vendor contractors to supply comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's established performance on numerous delivery orders issued between October 2 and October 15, 2025, demonstrates the company's capability to fulfill the specialized pharmaceutical requirements of the federal military medical system, with its product portfolio encompassing oncology treatments, immunosuppressants, vaccines, emergency medications, and routine pharmaceuticals across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DB26FPPA2?
SPE2DB26FPPA2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 17, 2025.
How much is contract SPE2DB26FPPA2 worth?
The government has obligated $9,284 on SPE2DB26FPPA2.
Is contract SPE2DB26FPPA2 an order under another contract?
Yes. SPE2DB26FPPA2 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB26FPPA2 competed?
The extent of competition for SPE2DB26FPPA2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award